Apolipoprotein E

Drug Profile

Apolipoprotein E

Alternative Names: Apo A4; Apo E; Apolipoprotein A1

Latest Information Update: 11 Feb 2008

Price : $50

At a glance

  • Originator Mitsubishi Chemical; Savient Pharmaceuticals
  • Class Antihyperlipidaemics
  • Mechanism of Action Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia; Kaposi's sarcoma

Most Recent Events

  • 02 Jul 2004 Nuvelo is not continuing development of Apolipoprotein E
  • 20 May 1999 Preclinical development for Kaposi's sarcoma in USA (Unknown route)
  • 08 Jan 1998 No-Development-Reported for Hyperlipidaemia in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top